Biodexa Pharmaceuticals annual ebitda margin
2015
2016
2017
2018
2022
2023
Biodexa Pharmaceuticals EBITDA Margin Growth & History (BDRX)
Biodexa Pharmaceuticals's ebitda margin was −1,879.53% for fiscal 2023.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2023 | 2023-12-31 | −1,879.53% | −721.87 pp |
| 2022 | 2022-12-31 | −1,157.65% | — |
| 2018 | 2018-12-31 | −602.79% | +733.31 pp |
| 2017 | 2017-12-31 | −1,336.10% | −608.21 pp |
| 2016 | 2016-12-31 | −727.89% | +209.71 pp |
| 2015 | 2015-12-31 | −937.60% | — |
Biodexa Pharmaceuticals ebitda margin trends
Over the last five fiscal years, Biodexa Pharmaceuticals's ebitda margin decreased from −602.79% to −1,879.53%, a change of −1276.74 percentage points.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...